

Unlock their potential – 15 years of biosimilars ^[1]

15 years ago, Sandoz launched the world's first biosimilar! Biosimilars have unique potential to increase patient access, relieve mounting pressures on already overburdened healthcare systems and stimulate innovation. Despite proven benefits for patients and healthcare systems, biosimilar uptake still varies greatly not only between countries and therapy areas, but also within countries. We must create an environment that fosters greater biosimilar adoption and prepare for the next wave of biosimilars that will enter the market over the next decade.

To unlock the full potential of biosimilars, we need to take long-term oriented action now. Together, let's unlock the full potential of biosimilars to ensure a successful future for patients, healthcare professionals and healthcare systems!

It's been a long and exciting adventure since we launched the world's first biosimilar in 2006. We asked several Sandoz associates these two questions:

- **How were things back THEN, when the first biosimilar was developed and launched?**

 - **15 years after the approval and launch of the world's first biosimilar, where are we NOW?**
-

-

Unlock Their Potential

Biosimilars, the key to driving access and sustainability

Biologics have revolutionized the treatment of many disabling and life-threatening diseases, however their high costs place a significant burden on healthcare systems and sometimes hinders patient access.¹

Proactive reforms to strengthen health systems and alleviate future pressures will be needed to address future challenges, especially post-COVID-19.



Over 70% of new drug approvals are expected to be biologic products by the year 2025.²



\$24.24 trillion Global spending on healthcare will double by 2040³

What are biosimilars?



- A follow-on medicine to a biological medicine ("reference medicine") for which the patent has expired and exclusivity has been lost.⁴
- Matches the reference medicine in terms of safety, quality and efficacy, so physicians and patients can expect the same clinical outcome.⁵
- Biosimilars are approved by the same regulatory authorities and are manufactured following the same high-quality standards as for the reference biologic.⁶

Why biosimilars?



Growing uptake of biosimilars has delivered significant benefits to healthcare systems since its approval in 2006, aiming to:^{7,8}

- Increase patient access by allowing biologics to be used earlier in the treatment journey
- Allow health systems to redirect funds so more patients can be treated
- Contribute to building sustainable health care systems
- Stimulate innovation in development of next-generation biologics
- Drive competition, resulting in increased treatment options and value-added services to support patient care and the healthcare community

[2]

- [Download as PDF](#) [2]

15 years of biosimilars – timeline

15 years ago, Sandoz launched the world's first biosimilar! In this timeline we show some major milestones for biosimilars overall and also some milestones for Sandoz biosimilars.

Related news

[How to solve the paradox of modern healthcare | LinkedIn](#) [3] by Richard Saynor

[15 years of biosimilar access in Europe: Learning from the past to shape the future | PharmaTimesMagazine](#) [4] by Rebecca Guntern

[Ushering in the next wave of biosimilars by unlocking their potential](#) [5]

Twitter

[Sandoz Moments](#) [6]

Featured image:

